Ensysce Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENSC research report →
About the company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology.
- CEO
- D. Lynn Kirkpatrick
- IPO
- 2018
- Employees
- 7
- HQ
- La Jolla, CA, US
Price Chart
- Market Cap
- $2.63M
- P/E
- -0.08
- P/S
- 1.81
- P/B
- -5.71
- EV/EBITDA
- -0.27
- Div Yield
- 0.00%
- Gross Margin
- -103.66%
- Op Margin
- -813.95%
- Net Margin
- -810.57%
- ROE
- -631.47%
- ROIC
- 2796.95%
- Revenue
- $5.07M · -2.75%
- Net Income
- $-10,175,700 · -27.40%
- EPS
- $-3.98 · 12.91%
- Op Income
- $-10,240,946
- FCF YoY
- -4.05%
- 52W High
- $2.75
- 52W Low
- $0.23
- 50D MA
- $0.31
- 200D MA
- $1.02
- Beta
- 0.82
- Avg Volume
- 2.23M
Get TickerSpark's AI analysis on ENSC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 2, 23 | GOWER BOB G | buy | 90,287 |
| Mar 1, 23 | GOWER BOB G | buy | 270,000 |
| Feb 28, 23 | GOWER BOB G | buy | 109,300 |
| Dec 9, 22 | GOWER BOB G | buy | 357,143 |
| Dec 9, 22 | GOWER BOB G | other | 714,286 |
| Jun 23, 22 | Chang William H | other | 15,000 |
| Jun 23, 22 | Martin Steven Robert | other | 15,000 |
| Jun 23, 22 | Rauch Lee M. | other | 15,000 |
| Jun 23, 22 | GOWER BOB G | other | 15,000 |
| Jun 23, 22 | GOWER BOB G | other | 15,000 |
Our ENSC coverage
Recent articles, reports, and earnings notes.
No research on ENSC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENSC report →Similar companies
Peers in the same neighborhood.